Antimicrobial Susceptibility Profiles of Escherichia coli Isolates from Clinical Cases of Geese in Hungary Between 2022 and 2023

2022年至2023年匈牙利鹅临床病例中大肠杆菌分离株的抗菌药物敏感性分析

阅读:1

Abstract

Background: Antimicrobial resistance (AMR) poses an increasing threat to animal health and food safety. In the poultry sector, particularly in waterfowl farming, the widespread use of antibiotics may contribute to the dissemination of resistant Escherichia coli strains. This study aims to map the antibiotic resistance profiles of E. coli isolates from geese in Hungary, determine the prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, and analyze resistance patterns and co-resistance relationships. Methods: E. coli isolates from clinical cases between 2022 and 2023 were examined using minimum inhibitory concentration (MIC) determination. Susceptibility results were evaluated based on the Clinical Laboratory Standard Institute (CLSI) breakpoints. Cluster analysis and principal component analysis (PCA) were applied to identify resistance patterns. Co-resistance relationships were examined through network analysis, while Monte Carlo simulations were used to estimate the expected prevalence of MDR strains. Results: Among the examined isolates, neomycin resistance was particularly high (86.8%), while florfenicol (73.6%) and amoxicillin (65.9%) resistance levels were also significant. The prevalence of MDR strains was 86.8%, and XDR strains accounted for 38.5%. Co-resistance analysis revealed a strong correlation between neomycin and spectinomycin resistance, as well as amoxicillin and doxycycline resistance. Monte Carlo simulations estimated that the expected range of MDR strain prevalence could vary between 80.2% and 92.3%. Conclusions: The high prevalence of MDR and XDR strains highlights the urgent need to reassess antibiotic usage strategies in goose farming. These findings underscore the importance of targeted antibiotic use, continuous microbiological surveillance, and the exploration of alternative therapeutic approaches to mitigate AMR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。